254 related articles for article (PubMed ID: 29047146)
21. [The populations attitudes to colorectal cancer screening in the Czech Republic].
Král N; Seifert B; Suchánek Š; Zavoral M; Májek O
Epidemiol Mikrobiol Imunol; 2015 Mar; 64(1):41-6. PubMed ID: 25872995
[TBL] [Abstract][Full Text] [Related]
22. Colonoscopy and fecal occult blood test use in Germany: results from a large insurance-based cohort.
Stock C; Ihle P; Schubert I; Brenner H
Endoscopy; 2011 Sep; 43(9):771-81. PubMed ID: 21830189
[TBL] [Abstract][Full Text] [Related]
23. Are we doing enough to screen for colorectal cancer? Findings from the 1999 Behavioral Risk Factor Surveillance System.
Seeff LC; Shapiro JA; Nadel MR
J Fam Pract; 2002 Sep; 51(9):761-6. PubMed ID: 12366896
[TBL] [Abstract][Full Text] [Related]
24. Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008.
Choi KS; Lee HY; Jun JK; Shin A; Park EC
J Gastroenterol Hepatol; 2012 Jun; 27(6):1070-7. PubMed ID: 22004224
[TBL] [Abstract][Full Text] [Related]
25. [Lesions detected in a colorectal cancer screening program in the Basque Country: first round (2009-2011)].
Portillo I; Idígoras I; Ojembarrena E; Arana E; Luis Hurtado J; Basurko R; Tapia M; Luz Peña M
Gastroenterol Hepatol; 2013 May; 36(5):301-8. PubMed ID: 23618538
[TBL] [Abstract][Full Text] [Related]
26. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
[TBL] [Abstract][Full Text] [Related]
27. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
[TBL] [Abstract][Full Text] [Related]
28. Fecal Occult Blood Test Results of the National Colorectal Cancer Screening Program in South Korea (2006-2013).
Rim JH; Youk T; Kang JG; Park BK; Gee HY; Kim JH; Yoo J
Sci Rep; 2017 Jun; 7(1):2804. PubMed ID: 28584248
[TBL] [Abstract][Full Text] [Related]
29. Using serum placenta growth factor could improve the sensitivity of colorectal cancer screening in fecal occult blood negative population: A multicenter with independent cohort validation study.
Wei SC; Tsao PN; Wang YT; Lin BR; Wu DC; Tsai WS; Chen JS; Wong JM
Cancer Med; 2019 Jul; 8(7):3583-3591. PubMed ID: 31063258
[TBL] [Abstract][Full Text] [Related]
30. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
31. Risk stratification and detection of new colorectal neoplasms after colorectal cancer screening with faecal occult blood test: experiences from a Danish screening cohort.
Bjerrum A; Milter MC; Andersen O; Fischer A; Lynge E
Eur J Gastroenterol Hepatol; 2015 Dec; 27(12):1433-7. PubMed ID: 26352132
[TBL] [Abstract][Full Text] [Related]
32. [Screening for colorectal cancer in high-risk and intermediate-risk subject: what's the best tool?].
Trevisani L; Cifalà V; Sartori S; Tombesi P; Matarese V; Pezzoli A; Abbasciano V
Recenti Prog Med; 2009 Feb; 100(2):68-72. PubMed ID: 19350797
[TBL] [Abstract][Full Text] [Related]
33. Screening and primary prevention of colorectal cancer: a review of sex-specific and site-specific differences.
Massat NJ; Moss SM; Halloran SP; Duffy SW
J Med Screen; 2013; 20(3):125-48. PubMed ID: 24197771
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal adherence with fecal occult blood test screening in community practice.
Fenton JJ; Elmore JG; Buist DS; Reid RJ; Tancredi DJ; Baldwin LM
Ann Fam Med; 2010; 8(5):397-401. PubMed ID: 20843880
[TBL] [Abstract][Full Text] [Related]
35. Impact of Screening Program on Incidence of Colorectal Cancer: A Cohort Study in Italy.
Giorgi Rossi P; Vicentini M; Sacchettini C; Di Felice E; Caroli S; Ferrari F; Mangone L; Pezzarossi A; Roncaglia F; Campari C; Sassatelli R; Sacchero R; Sereni G; Paterlini L; Zappa M
Am J Gastroenterol; 2015 Sep; 110(9):1359-66. PubMed ID: 26303133
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
[TBL] [Abstract][Full Text] [Related]
37. [Screening of high-risk group with colorectal cancer].
Xu AG; Yu ZJ; Zhong XH; Gan AH; Liu JH; Luo QY
Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(2):116-8. PubMed ID: 20356496
[TBL] [Abstract][Full Text] [Related]
38. Colorectal cancer test use--Maryland, 2002-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(36):932-6. PubMed ID: 17851446
[TBL] [Abstract][Full Text] [Related]
39. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
[TBL] [Abstract][Full Text] [Related]
40. Accuracy of self-checked fecal occult blood testing for colorectal cancer in Thai patients.
Lohsiriwat V
Asian Pac J Cancer Prev; 2014; 15(18):7981-4. PubMed ID: 25292099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
